Abstract:Glioblastoma multiforme (GBM) is a common and aggressive brain cancer with a median survival rate of 12 to 18 months after diagnosis. Despite standard treatments, including surgery, radiotherapy, and Temozolomide (TMZ), GBM remains highly resistant to therapy due to its infiltrative pattern of invasion, rapid growth, and propensity to relapse [1]. While overall mortality rates remain high, there is a crucial need for a better understanding of the molecular mechanisms and gene mutations involved in GBM and the development of more effective and adaptive therapeutic approaches. Modulating reactive oxygen species (ROS) levels has been suggested as a therapeutic strategy to selectively target the destruction of cancer cells. To address this, we propose a combination therapy utilizing multi-operational plasma devices, including using cold atmospheric plasma (CAP) jet and plasma discharge tube (PDT) in conjunction with TMZ for GBM treatment. CAP functions by elevating reactive oxygen and nitrogen species (RONS) levels and specifically targeting tumor spread. We investigated various plasma devices and their characteristics using optical emission spectroscopy (OES) and measured the electromagnetic potential and emissions of the PDT. The OES of PDT displayed a similar spectrum as the CAP jet, indicating the presence of ROS. In this study, we performed transcriptomic analysis of glioblastoma cells using high throughput deep RNA-Seq with next-generation sequencing (NGS) to quantify genome-wide gene expression changes. Additionally, we examined signaling pathways and predicted structural changes in consequential proteins caused by gene spectrum up or down-regulation. Our results demonstrate that the combination treatment of CAP and TMZ downregulated vital genes involved in MAPK, P53, DNA repair, and cell cycle pathways. The combination of CAP & TMZ showed a significant antitumor effect, inducing apoptosis and damaging essential proteins in GBM cells. In vitro and microscopic studies verified these results, showing nuclear and cell membrane disruption in cancer cells post-plasma treatment. Our findings demonstrate that the combination of CAP/PDT and TMZ effectively sensitizes GBM cells to TMZ, leading to apoptosis. We have previously shown a non-invasive application of CAP jet on the skull of tumor-bearing mice causing ~78% tumor inhibition [2]. Our current study highlights the potential of PDT for non-invasive treatment in vitro, offering a modality for intracranial delivery in in-vivo models. In conclusion, we propose CAP/PDT and TMZ combination therapy as novel non-invasive treatments for GBM in murine models. This approach offers a promising avenue for addressing the dire need for more effective treatments with minimal impact on normal cells. Further investigations and validation in clinical settings are warranted to significantly improve GBM management and patient outcomes. References: [1] Tan, A. C. et al. Management of glioblastoma: State of the art and future directions. CA: 70, 299–312 (2020) [2] Soni, V.; et al., Cancers, 13, 4485 (2021). Citation Format: Vikas Soni, Alex Horkowitz, Li Lin, Jonathan Sherman, Michael Keidar. Synergistic antitumor effects of cold atmospheric plasma and temozolomide in glioblastoma: multimodal approaches integrating in-vitro, in vivo, and in silico investigations for novel and enhanced therapeutic advancements [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr B030.

Abstract A017: Cell-specific photodynamic therapy for high grade gliomas

Abstract 7593: Photodynamic therapy improves therapeutic management of glioblastoma

Feasibility of Photodynamic Therapy for Glioblastoma with the Mitochondria-Targeted Photosensitizer Tetramethylrhodamine Methyl Ester (TMRM)

Using Light for Therapy of Glioblastoma Multiforme (GBM)

Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins

Surg-18. Innovative Drug-Device Combination For The Photodynamic Treatment Of Primary Glioblastoma (Gbm) Patients

Gene Therapy for High Grade Glioma: The Clinical Experience

Abstract B030: Synergistic antitumor effects of cold atmospheric plasma and temozolomide in glioblastoma: multimodal approaches integrating in-vitro, in vivo , and in silico investigations for novel and enhanced therapeutic advancements

Abstract 5680: Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies

Dddr-38. Translational Steps Of The Antitumor Peptide Tat-Cx43266-283 As A Treatment For Glioblastoma: Egfr As A Treatment Response Biomarker And Results Of Combination Therapy In A Preclinical Resection Model

Enhancing Drug Delivery for Overcoming Angiogenesis and Improving the Phototherapy Efficacy of Glioblastoma by ICG-Loaded Glycolipid-Like Micelles

Abstract 7229: In situ trans-differentiation therapy effectively terminates the growth and recurrence of glioblastoma

Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma

Targeted Radiolabeled Compounds in Glioma Therapy

Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.

Establishing Genetic and Molecular Markers of Sensitivity to a Novel and Potent Tetracyclic Terpenoid Therapy Against High-Grade Gliomas

Abstract B046: Irradiation of patient-derived high-grade gliomas reduces 5-ALA-induced fluorescence utility during re-resection

Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro

Donor Substitution Engineering of Hemicyanine Nanoparticles to Reprogram the Tumor Microenvironment and Enhance Fn14‐Targeted BiTE for Glioblastoma Photoimmunotherapy

Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies

Enhancing Selective Photosensitizer Accumulation and Oxygen Supply for High-Efficacy Photodynamic Therapy Toward Glioma by 5-Aminolevulinic Acid Loaded Nanoplatform